USFDA14 Aug 2026, 09:42 am
Aurobindo Pharma Subsidiary Receives US FDA Warning Letter
AI Summary
Aurobindo Pharma Ltd. announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has received a Warning Letter from the US FDA for its Unit 1 facility. This follows an Official Action Indicated (OAI) status previously received by the unit. The company stated that there will be no impact on existing supplies to the US market. Unit 1 contributes approximately 2% to the company's overall group revenue. Aurobindo Pharma is committed to working with the US FDA and enhancing its compliance.
Key Highlights
- Eugia Pharma Specialities Ltd. Unit 1 received a US FDA Warning Letter.
- No impact expected on existing US market supplies.
- The affected unit contributes ~2% to group revenue.
- Company committed to enhancing compliance with US FDA.
Price Impact
More from AUROPHARMA